Rhumbline Advisers Akebia Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 265,389 shares of AKBA stock, worth $504,239. This represents 0.0% of its overall portfolio holdings.

Number of Shares

265,389

Previous 242,876 9.27%

Holding current value

$504,239

Previous $320,000 54.06%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$1.26 - $2.13 $28,366 - $47,952	22,513 Added 9.27%	265,389 $493,000
Q3 2024 Nov 12, 2024	SELL	$0.94 - $1.55 $3,932 - $6,485	-4,184 Reduced 1.69%	242,876 $320,000
Q2 2024 Aug 01, 2024	BUY	$0.86 - $1.63 $208,235 - $394,678	242,134 Added 4915.43%	247,060 $252,000
Q2 2023 Aug 08, 2023	BUY	$0.51 - $1.43 $2,512 - $7,044	4,926 New	4,926 $4,000
Q2 2022 Aug 11, 2022	SELL	$0.32 - $0.67 $65,619 - $137,391	-205,062 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.72 - $2.93 $4,358 - $17,735	-6,053 Reduced 2.87%	205,062 $147,000
Q4 2021 Feb 10, 2022	BUY	$2.26 - $3.34 $1,819 - $2,688	805 Added 0.38%	211,115 $477,000
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $17,274 - $28,521	7,351 Added 3.62%	210,310 $606,000
Q2 2021 Aug 05, 2021	BUY	$2.83 - $4.2 $81,271 - $120,615	28,718 Added 16.48%	202,959 $769,000
Q1 2021 May 06, 2021	SELL	$2.92 - $5.06 $43,332 - $75,090	-14,840 Reduced 7.85%	174,241 $590,000
Q4 2020 Feb 10, 2021	BUY	$2.22 - $3.78 $29,004 - $49,385	13,065 Added 7.42%	189,081 $529,000
Q3 2020 Nov 12, 2020	SELL	$2.39 - $13.08 $79,307 - $434,033	-33,183 Reduced 15.86%	176,016 $442,000
Q2 2020 Aug 13, 2020	SELL	$6.67 - $13.58 $36,631 - $74,581	-5,492 Reduced 2.56%	209,199 $2.84 Million
Q1 2020 May 06, 2020	BUY	$4.1 - $10.24 $126,234 - $315,279	30,789 Added 16.74%	214,691 $1.63 Million
Q4 2019 Feb 05, 2020	BUY	$3.16 - $6.73 $20,995 - $44,714	6,644 Added 3.75%	183,902 $1.16 Million
Q3 2019 Oct 23, 2019	BUY	$3.55 - $5.4 $57,009 - $86,718	16,059 Added 9.96%	177,258 $695,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $200,485 - $393,636	48,899 Added 43.54%	161,199 $780,000
Q1 2019 May 01, 2019	SELL	$5.41 - $8.73 $49,214 - $79,416	-9,097 Reduced 7.49%	112,300 $920,000
Q4 2018 Jan 31, 2019	BUY	$5.39 - $9.15 $410,518 - $696,891	76,163 Added 168.38%	121,397 $671,000
Q3 2018 Nov 07, 2018	SELL	$7.44 - $10.65 $17,952 - $25,698	-2,413 Reduced 5.06%	45,234 $399,000
Q2 2018 Aug 06, 2018	BUY	$9.15 - $11.34 $60,435 - $74,900	6,605 Added 16.09%	47,647 $476,000
Q1 2018 May 02, 2018	BUY	$9.53 - $15.68 $2,573 - $4,233	270 Added 0.66%	41,042 $391,000
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $56,860 - $78,222	-3,993 Reduced 8.92%	40,772 $606,000
Q3 2017 Nov 06, 2017	BUY	$13.06 - $19.67 $584,630 - $880,527	44,765	44,765 $881,000

Others Institutions Holding AKBA

# of Institutions

128

Shares Held

63.3M

Call Options Held

50.6K

Put Options Held

203K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Akebia Therapeutics, Inc. Transaction History